of the drug. The full search strategy for MEDLINE was given in the report as an example; this was adjusted, where required, for use with other databases.
The primary outcomes in the review were assessments of obesity or overweight status. These were measured as: changes in the body weight, including absolute or percentage changes; fat content, including the body mass index, ponderal index, skin-fold thickness, fat-free mass and fat change; or fat distribution, including waist size, waist-to-hip ratio, and girth-to-height ratio.
Only studies reporting baseline and post-intervention measurements were included.
The secondary outcomes included physiological changes such as changes in glycaemic control in diabetes, changes in lipid profiles, and changes in blood-pressure.
How were decisions on the relevance of primary studies made?
The titles and abstracts of all the identified studies were assessed independently by two reviewers. If either or both considered the study to be possibly relevant, a hard copy was obtained and the inclusion criteria were applied by two of the reviewers. Any disagreements were resolved by discussion or by recourse to a third reviewer.
Assessment of study quality
Each trial was assessed using a comprehensive checklist for methodological quality (details provided), which considered the following: the method of randomisation; participant selection criteria; the sample size; comparability of treatment arms; blinding; statistical analysis; and description of withdrawals. Economic appraisals were also quality assessed using a checklist (details given). Validity was judged independently by two reviewers with any disagreements resolved through discussion.
Data extraction
The following categories of data were extracted: the authors; the year of publication; the country in which the study was conducted; the aim of the study; the method of randomisation; the outcomes which were measured; the setting of the treatment; the duration of both treatment and follow-up; participant selection criteria; baseline comparability of the groups; intervention characteristics; results for each treatment group; incidence of adverse effects; the number of withdrawals; and the reason for withdrawals.
The data were extracted by one reviewer into standardised structured tables, which were checked by a second reviewer. Any disagreements were resolved through discussion.
In cases of multiple publications, all the publications were examined to ensure all the relevant data were recorded. However, the data were presented as a single entry.
Methods of synthesis
How were the studies combined? A narrative summary of the results was presented, with the results grouped according to the study end point and the type of weight management programme (weight loss or weight maintenance). The results from groups of studies that were considered to be sufficiently similar were pooled statistically. A random-effects model was used to calculate a weighted mean difference for continuous data, and a relative risk for dichotomous data, along with the associated 95% confidence intervals (CIs). All statistical manipulations were conducted using Metaview software (version 4.1).
No method of assessing publication bias was reported.
How were differences between studies investigated?
The heterogeneity of each statistical pooling was assessed using the chi-squared test, where a p-value of less than 0.10 was judged to be statistically significant. 
Results of the review
A total of 14 RCTs were included: 11 published RCTs (6,219 patients) investigating the use of orlistat, and 3 RCTs (number of patients not reported) submitted by the drug manufacturers.
11 RCTs on orlistat met the inclusion and exclusion requirements. The drug manufacturer submitted an unspecified number of trials, of which 3 met the inclusion criteria. No data were presented on the number of trials that were excluded for having a duration of less than one year.
Two economic evaluations, one of which was submitted by the manufacturer, were included in the cost-effectiveness evaluation.
Most of the trials showed greater weight loss and better weight maintenance with orlistat, compared with placebo, at all end points; the differences for both outcomes were statistically significant.
Orlistat administered at a dose of 120 mg t.d.s. was the optimum regimen in terms of weight loss. Most trials showed significant improvement in at least some lipid concentration parameters and, in 3 RCTs, orlistat produced statisticallysignificant reductions in blood-pressure relative to placebo.
In obese patients with type II diabetes, orlistat resulted in a significantly greater weight loss at 1 year, compared with placebo. Some parameters of glycaemic control and lipid concentration also showed significantly greater improvements when compared with placebo.
The incidence of gastrointestinal adverse events was consistently higher in the orlistat groups than in the placebo groups. Orlistat use was associated with lower serum levels of fat-soluble vitamins.
One economic appraisal of orlistat was located by the search strategy; this was supplemented by a submission by the manufacturer.
Cost information
A published cost-utility analysis of orlistat for the treatment of obesity used data from 3 RCTs, each of which was included in the present review. The intervention tested consisted of orlistat (120 mg/day) combined with a hypocalorific diet, compared with a hypocalorific diet plus a placebo preparation. Only the direct costs to the NHS were included in the analysis. The average cost of orlistat for 100 patients treated over 2 years was £73,436 (1999 figures) . The incremental cost-utility of orlistat treatment was £45, 881 (95% CI: 19, 452, 55, 391) . Additionally, a cost-utility analysis was submitted by the manufacturer to the reviewers, in confidence.
Authors' conclusions
Although many trials demonstrated statistically-significant differences between the groups in terms of weight loss in favour of orlistat versus placebo, the differences may not always be of clinical significance. The clinical significance of between-group differences for secondary outcomes may also be debatable. The potential adverse effects should be taken into account when prescribing orlistat, particularly gastrointestinal effects.
CRD commentary
The review question was clearly defined in terms of the participants, intervention, comparators and outcomes. The inclusion and exclusion criteria were appropriate for the research question.
The literature search was extensive with a wide range of sources being searched. While language restrictions were applied, it is unlikely that a large number of studies were missed owing to the range of languages included. No attempt to track unpublished material or contact authors, other than the manufacturers, was reported. Thus, it is possible that some studies were missed.
The validity of both the clinical-effectiveness and cost-effectiveness studies was assessed and reported in an appropriate manner. The items included in the checklists appear to have been appropriate indicators of methodological validity. The extraction, presentation and analysis of the data was conducted appropriately.
